References of "Belaiche, Jacques"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA patient who survived total colonic ulcerative colitis surinfected by cytomegalovirus complicated by toxic megacolon and disseminated intravascular coagulation
Laurent, S.; Reenaers, Catherine ULg; Detroz, Bernard ULg et al

in Acta Gastro-Enterologica Belgica (2005), 68(2, Apr-Jun), 276-279

The authors report the case of a patient aged 60-year-old who survived ulcerative colitis complicated by toxic megacolon and disseminated intravascular coagulation. This patient was not known for this ... [more ▼]

The authors report the case of a patient aged 60-year-old who survived ulcerative colitis complicated by toxic megacolon and disseminated intravascular coagulation. This patient was not known for this ulcerative colitis and was first hospitalised for a suspicion of diverticulitis. The admission symptoms were fever, abdominal pain and bloody diarrhoea. The evolution was defavorable under antibiotics and sulfasalazine. The patient was readmitted 5 days after he left hospital, and the diagnosis of UC was based on colon biopsy made during the first hospitalisation. A treatment with methylprednisolone was started and the patient worsened day by day with apparition of toxic megacolon and disseminated intravascular coagulation. Subtotal colectomy was performed for degradation of general status and coagulation factors. Pathological findings confirmed ulcerative colitis with toxic megacolon. Cytomegalovirus inclusions were demonstrated on the colonic specimen and confirmed by PCR. In this report the authors discuss the etiology of toxic megacolon and disseminated intravascular coagulation in ulcerative colitis surinfected by cytomegalovirus. Mortality of these pathologies is high necessitating rapid diagnosis of cytomegalovirus infection by sigmoid biopsy. Management requires immunosupression interruption and ganciclovir therapy, or surgery in unsuccessful medical treatment. [less ▲]

Detailed reference viewed: 50 (5 ULg)
Full Text
Peer Reviewed
See detailIncreased expression of receptor activator of NF-kappa B ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients
Franchimont, N.; Reenaers, Catherine ULg; Lambert, Chantal ULg et al

in Clinical & Experimental Immunology (2004), 138(3), 491-498

Crohn's disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor ... [more ▼]

Crohn's disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin (OPG) are potentially involved in this process as they regulate osteoclastogenesis and are influenced by pro-inflammatory cytokines. The aim of this study was to determine the levels of soluble RANKL (sRANKL), RANK and OPG expression both in the serum and in the colon of CD patients. Levels of sRANKL and OPG were assessed in the serum and the supernatants of cultured colonic biopsies in patients with CD and controls by ELISA. RANK expression was explored by immunostaining and immunofluorescence of fixed colonic samples. OPG and sRANKL levels were higher in the serum of CD patients as compared to age- and sex-matched controls. Levels of sRANKL and OPG were significantly enhanced in cultured colonic biopsies from CD, and OPG levels correlated with histological inflammation, and pro- and anti-inflammatory cytokine levels. No significant correlation was found for sRANKL. RANK(+) cells were increased in the colon of CD, particularly in inflamed areas. These cells were positive for CD68 or S100 protein. We conclude that serum and local levels of sRANKL and OPG are increased in CD. Moreover, RANK is expressed in the colonic mucosa by subpopulations of activated macrophages or dendritic cells at higher levels in CD compared to normal colon. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailRapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Franchimont, N.; Putzeys, V.; Collette, Julien ULg et al

in Alimentary Pharmacology & Therapeutics (2004), 20(6), 607-614

BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab ... [more ▼]

BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab. METHODS: We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group. RESULTS: Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14-51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30-61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter. CONCLUSION: Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailAssociation between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
Louis, Edouard ULg; El Ghoul, Z.; Vermeire, S. et al

in Alimentary Pharmacology & Therapeutics (2004), 19(5), 511-519

AIM: To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for FcgammaRIIIa, which is expressed on macrophages and natural killer cells, is involved in antibody ... [more ▼]

AIM: To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for FcgammaRIIIa, which is expressed on macrophages and natural killer cells, is involved in antibody-dependent cell-mediated cytotoxicity and has recently been associated with a positive response to rituximab, a recombinant immunoglobulin G1 antibody used in non-Hodgkin's lymphomas) and response to infliximab in Crohn's disease. METHODS: FCGR3A-158 polymorphism was determined using an allele-specific polymerase chain reaction assay in 200 Crohn's disease patients who had received infliximab for either refractory luminal (n = 142) or fistulizing (n = 58) Crohn's disease. Clinical and biological responses (according to C-reactive protein levels) were assessed in 200 and 145 patients, respectively. RESULTS: There were 82.9% clinical responders in V/V patients vs. 72.7% in V/F and F/F patients (N.S.). Globally, the decrease in C-reactive protein was significantly higher in V/V patients than in F carriers (P = 0.0078). A biological response was observed in 100% of V/V patients, compared with 69.8% of F carriers (P = 0.0002; relative risk, 1.43; 95% confidence interval, 1.27-1.61). In the sub-group of patients with elevated C-reactive protein before treatment, the multivariate analysis selected the use of immunosuppressive drugs and FCGR3A genotype as independent factors influencing the clinical response to infliximab (P = 0.003). CONCLUSION: Crohn's disease patients with FCGR3A-158 V/V genotype have a better biological and, possibly, clinical response to infliximab. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailHpatitis C infection: eligibility for antiviral therapies
El souda, R; DELWAIDE, Jean ULg; GERARD, Christiane ULg et al

in Acta Gastro-Enterologica Belgica (2004), 67

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailHCV genotype 5: an easy to treat population
REENAERS, Catherine ULg; DELWAIDE, Jean ULg; GERARD, Christiane ULg et al

in Acta Gastro-Enterologica Belgica (2004), 67

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailHCV genotype 4 in Belgium: epidemiological characteristics
REENAERS, Catherine ULg; DELWAIDE, Jean ULg; GERARD, Christiane ULg et al

in Acta Gastro-Enterologica Belgica (2004), (67), 03

Detailed reference viewed: 27 (0 ULg)
Full Text
Peer Reviewed
See detailLa video-capsule endoscopique: une nouvelle methode d'exploration du grele
Dupont, P.; Louis, Edouard ULg; Belaiche, Jacques ULg

in Revue Médicale de Liège (2004), 59(7-8, Jul-Aug), 445-50

Capsule endoscopy is a new technique of exploration which enables to visualize the entire small bowel. Occult or unexplained digestive bleeding currently constitutes on major indication of this technique ... [more ▼]

Capsule endoscopy is a new technique of exploration which enables to visualize the entire small bowel. Occult or unexplained digestive bleeding currently constitutes on major indication of this technique. The aim of this study is to report the results obtained among 15 patients investigated by capsule endoscopy and to discuss the place of this new technique in the small bowel exploration. [less ▲]

Detailed reference viewed: 359 (1 ULg)
Full Text
Peer Reviewed
See detailImpact of osteoarthritis and chronic back pain on health-related quality of life among patients on NSAIDS
Rabenda, Véronique ULg; Ethgen, Olivier ULg; Belaiche, Jacques ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 89-90

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailUse of healthcare resources related to gastrointestinal toxicity of NSAIDS
Rabenda, Véronique ULg; Belaiche, Jacques ULg; Raeman, F. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 14

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailEarly development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype
Louis, Edouard ULg; Michel, V.; Hugot, J. P. et al

in Gut (2003), 52(4), 552-557

Background: Crohn's disease is a heterogeneous entity. Disease behaviour, characterised as structuring, penetrating, or non-stricturing non-penetrating, is a clinically important phenotype as it is ... [more ▼]

Background: Crohn's disease is a heterogeneous entity. Disease behaviour, characterised as structuring, penetrating, or non-stricturing non-penetrating, is a clinically important phenotype as it is associated with complications and need for surgery. It has recently been showed that the behaviour of Crohn's disease changes over the course of the disease. Aim: To assess the association between rapid development of a penetrating or stricturing pattern of Crohn's disease and demographic and clinical characteristics as well as NOD2/CARD15 genotype. Patients and methods: A total of 163 patients with a firm diagnosis of Crohn's disease and who had non-penetrating non-stricturing disease at diagnosis were studied. Various demographic and clinical characteristics as well as anitsaccharomyces cerevisiae antibody status and NOD2/CARD15 genotype were documented in these patients. These characteristics were compared in subgroups of patients according to evolution of disease behaviour five years after diagnosis. Results: Five years after diagnosis there were 110 (67.5%) patients with non-structuring non-penetrating disease, 18 (11%) with stricturing disease, and 35 (21.5%) with penetrating disease. In multivariate analysis, only disease location and number of flares per year were significantly discriminant between the three subgroups (p=0.0009 and 0.0001, respectively). Ileal location of the disease was associated with a stricturing pattern while a high number of flares was associated with a penetrating pattern. Active smoking was also associated with a penetrating pattern compared with a non-stricturing non-penetrating pattern only. Conclusions: Early development of stricturing or penetrating behaviour in Crohn's disease is influenced by disease location, clinical activity of the disease, and smoking habit, but not by NOD2/CARD15 genotype. [less ▲]

Detailed reference viewed: 18 (7 ULg)
Full Text
Peer Reviewed
See detailPrevention primaire et secondaire du cancer colorectal
Polus, Marc ULg; Piront, Patricia ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2003), 58(4), 247-53

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed ... [more ▼]

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed, particularly by aspirin and non steroidal anti-inflammatory drugs. Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality. [less ▲]

Detailed reference viewed: 116 (2 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. La maladie de still de l'adulte: une cause rare d'hepatite aigue febrile
Michels, V.; Delwaide, Jean ULg; Vermeulen, P. et al

in Revue Médicale de Liège (2003), 58(12), 729-733

A 63-year-old woman was hospitalized for the third time in one year for asthenia, fever and chills, jaundice, cytolysis and cholestasis. An adult onset Still's disease was diagnosed. Hepatic ... [more ▼]

A 63-year-old woman was hospitalized for the third time in one year for asthenia, fever and chills, jaundice, cytolysis and cholestasis. An adult onset Still's disease was diagnosed. Hepatic manifestations, diagnostic criteria and efficient therapy of AOSD will be reviewed. [less ▲]

Detailed reference viewed: 76 (5 ULg)
Full Text
Peer Reviewed
See detailOptimizing treatment with thioguanine derivatives in inflammatory bowel disease.
Louis, Edouard ULg; Belaiche, Jacques ULg

in Bailliere's Best Practice & Research. Clinical Gastroenterology (2003), 17(1), 37-46

Thioguanine derivatives, azathioprine and 6-mercaptopurine, represent major drugs in the treatment of chronic active inflammatory bowel disease. They are effective in two-thirds of the patients and safe ... [more ▼]

Thioguanine derivatives, azathioprine and 6-mercaptopurine, represent major drugs in the treatment of chronic active inflammatory bowel disease. They are effective in two-thirds of the patients and safe over the long term in patients who can tolerate them (80-90%). Recent progress in understanding the metabolism of these drugs and its implication in clinical practice have brought up new tools and strategies that are proposed to optimize treatment. In particular, the measurement and characterization of key enzymes and metabolites may have clinical impact. Thus, thiopurine methyl transferase genotyping and activity measurement, as well as erythrocytes, 6-thioguanine nucleotides and 6-methyl mercaptopurine levels, may help in some situations of intolerance or inefficacy with these drugs. Indications for starting and stopping treatment with thioguanine derivatives are also discussed. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailSubocclusion colique precoce apres traitement d'une maladie de Crohn refractaire active par infliximab.
Belaiche, Jacques ULg; Louis, Edouard ULg

in Gastroentérologie Clinique et Biologique (2003), 27(11), 1045-7

Detailed reference viewed: 86 (4 ULg)
Full Text
See detailRevue de l'épidémiologie de la maladie de Crohn en Europe
Piront, Patricia ULg; Belaiche, Jacques ULg; Louis, Edouard ULg

in Acta Endoscopica (2003), 33

Detailed reference viewed: 45 (2 ULg)
Full Text
Peer Reviewed
See detailNegative association between smoking and anti-saccharomyces cerevisiae antibodies in Crohn's disease
Van Kemseke, Catherine ULg; Belaiche, Jacques ULg; Steeman, C. et al

in Acta Gastro-Enterologica Belgica (2003), 66(1, Jan-Mar), 1-6

Background: Crohn's disease (CD) is a polygenic multifactorial heterogeneous disease. Anti-Saccharomyces Cerevisiae antibodies (ASCA) correlate highly with CD and are present in 50-80% of patients. The ... [more ▼]

Background: Crohn's disease (CD) is a polygenic multifactorial heterogeneous disease. Anti-Saccharomyces Cerevisiae antibodies (ASCA) correlate highly with CD and are present in 50-80% of patients. The reason for ASCA positivity or negativity in CD is unknown. The aim of our work was to analyse clinical, epidemiological and genetic characteristics in ASCA + or ASCA- CD patients. Methods : 113 patients with CD were tested for ASCA (IgA and IgG) by using a commercial kit (Medipan Diagnostica). Age, gender, systemic manifestations, familial form of disease, age at diagnosis, location and behaviour of the disease, smoking habit as well as genotyping for -308 TNF gene polymorphisms were determined. Results : 38.9% CD patients were negative for both IgA and IgG ASCA while 61.1% were ASCA positive (respectively IgA and IgG : 31.9%; IgA only : 9.7%; IgG only : 19.5%). The only significant difference between ASCA+ and ASCA- patients was for smoking habit : there were 29% smokers in ASCA+ versus 50% in ASCA- CD patients (P = 0.03). This low proportion of smokers was more prominent in ASCA IgA+ patients than in isolated ASCA IgG+ patients (25.6% versus 45.5%) and was minimal in patients with high titers of ASCA IgA (0/8). Logistic regression showed smoking habit still borderline for significance (P = 0.057). Conclusions : Our results suggest a negative association between smoking and ASCA positivity in CD. This association was more prominent for ASCA IgA+. It indicates that smoking habit should be taken into account when analysing ASCA status in CD patients and may suggest an influence of smoking on immunization against intestinal material. [less ▲]

Detailed reference viewed: 36 (0 ULg)
Full Text
Peer Reviewed
See detailClassification of Crohn's disease - Vienna and Beyond
Louis, Edouard ULg; Belaiche, Jacques ULg

in Inflammatory Bowel Disease Monitor (2003), 5

Detailed reference viewed: 64 (51 ULg)